Welcome to Ora Biomedical, Inc.
Healthy aging therapies for next generation medicine
Ora Biomedical develops small molecule therapeutics that extend lifespan and delay chronic illness by targeting the underlying molecular mechanisms of aging
See Matt Kaeberlein talk about the MMC!
The million-molecule challenge - a moonshot project to rapidly advance longevity intervention discovery
Preclinical discovery at our foundations
We set ourselves apart in longevity biotechnology by having the largest preclinical drug screening operation of its kind. This is possible with the WormBot-AI, an automated high-throughput robotics platform combined with state-of-the-art AI-based data analysis. By measuring health and survival in the small animal C. elegans, we can screen up to 144 populations in parallel with a single WormBot-AI. We use this powerful system to identify small molecule gerotherapeutics that modify normal aging and age-related disease pathology. Our team combines this innovative platform with decades of research excellence to provide best-in-class discovery science.
An evolutionary approach
Our translational geroscience approach identifies small molecules and natural products that target evolutionarily conserved aging mechanisms. Interventions targeting these mechanisms are screened across age-associated and rare disease models. Broad acting gerotherapeutics are then validated in mammalian studies on the path to clinical approval.
Developing the future of preventative medicine
Aging is the greatest predisposing factor to the chronic illnesses and diseases that limit quality lifespan and ultimately lead to death. Targeting the underlying mechanisms of aging using gerotherapeutics holds the promise to extend both maximal lifespan and increase the number of years spent in good health.
Follow us on social media for the latest company updates and geroscience news!!!